Stock Analysis
- China
- /
- Healthcare Services
- /
- SZSE:002589
Realcan Pharmaceutical Group First Quarter 2024 Earnings: EPS: CN¥0.01 (vs CN¥0.014 in 1Q 2023)
Realcan Pharmaceutical Group (SZSE:002589) First Quarter 2024 Results
Key Financial Results
- Revenue: CN¥2.02b (down 2.6% from 1Q 2023).
- Net income: CN¥15.2m (down 28% from 1Q 2023).
- Profit margin: 0.8% (down from 1.0% in 1Q 2023).
- EPS: CN¥0.01 (down from CN¥0.014 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Realcan Pharmaceutical Group shares are up 8.5% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Realcan Pharmaceutical Group (1 can't be ignored) you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Realcan Pharmaceutical Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:002589
Realcan Pharmaceutical Group
Sells medicines, medical devices, and medical consumables to medical institution worldwide.
Mediocre balance sheet and slightly overvalued.